This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Genetic Factors Affecting the Severity of Beta Thalassemia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Deborah Rund, Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00159042
First received: September 9, 2005
Last updated: August 9, 2017
Last verified: August 2017
  Purpose
Patients with genetic diseases can have widely differing severities. We are looking for genetic factors which influence the severity of beta thalassemia.

Condition
Beta Thalassemia

Study Type: Observational
Study Design: Observational Model: Other
Time Perspective: Other
Official Title: Identification of Novel Genetic Modifiers in Beta-thalassemia

Resource links provided by NLM:


Further study details as provided by Deborah Rund, Hadassah Medical Organization:

Biospecimen Retention:   Samples With DNA
DNA isolated from peripheral blood

Enrollment: 50
Actual Study Start Date: July 2004
Study Completion Date: July 1, 2017
Primary Completion Date: July 1, 2017 (Final data collection date for primary outcome measure)
Detailed Description:
The understanding of the phenotypic variability of genetically homogeneous disorders represents a major challenge. In beta thalassemia, the beta globin gene is affected by a variety of mutations. The group of patients to be analyzed here is homozygous for a splice site mutation that is common in the Middle East. In contrast to this genetic homogeneity, the spectrum of the clinical phenotype ranges from mild anemia to most severe, transfusion dependent anemia. We will use a genetic linkage approach to identify modifying factors and by analyzing the efficiency of an mRNA surveillance mechanism that is referred to as nonsense-mediated decay and represents a candidate genetic modifier of beta thalassemia and other genetic disorders.
  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients analyzed for beta thalassemia in our laboratory in Hadassah.
Criteria

Inclusion Criteria:

  • Identification of homozygous IVS1 nt 6 beta thalassemia mutation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00159042

Locations
Israel
Hadassah Medical Organization
Jerusalem, Israel, IL91120
Sponsors and Collaborators
Deborah Rund
Investigators
Principal Investigator: Ariella Oppenheim, PhD Hadassah Medical Organization
  More Information

Publications:
Responsible Party: Deborah Rund, Senior Hematologist, Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00159042     History of Changes
Other Study ID Numbers: 302803-HMO-CTIL
Study First Received: September 9, 2005
Last Updated: August 9, 2017

Additional relevant MeSH terms:
Thalassemia
beta-Thalassemia
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on August 18, 2017